Peter Davis (@peter_brit) header
Peter Davis (@peter_brit) profile picture

Disclaimer: I am not a financial advisor. Conduct your own due diligence. Regulatory outcomes are subject to clinical data and agency discretion.

England
Joined July 2021
Photo by Peter Davis (@peter_brit)Photo by Peter Davis (@peter_brit)Photo by Peter Davis (@peter_brit)Photo by Peter Davis (@peter_brit)Photo by Peter Davis (@peter_brit)Photo by Peter Davis (@peter_brit)Photo by Peter Davis (@peter_brit)Photo by Peter Davis (@peter_brit)Photo by Peter Davis (@peter_brit)Photo by Peter Davis (@peter_brit)
Peter Davis retweeted
$NWBO Will FDA be the next? This week the MHRA and the Saudi Food and Drug Authority (SFDA) signed a new Memorandum of Understanding, strengthening our partnership and creating a framework for closer regulatory cooperation, information exchange and sharing of expertise. linkedin.com/posts/mhra-sfda… SFDA and Singapore’s Health Sciences Authority Sign MoU to Strengthen Regulatory Cooperation and Knowledge Exchange sfda.gov.sa/en/news/19512 SFDA CEO and South Korea’s Minister of Food and Drug Safety Discuss Strengthening Cooperation on Food Safety and Drug Evaluation sfda.gov.sa/en/news/19830
1
5
25
742
Peter Davis retweeted
$NWBO Feels like MHRA is moving fast now. MHRA should know that SFDA launched NADR program three months ago. The Kingdom of Saudi Arabia has made biotech a national mandate with the ambition of becoming a regional hub by 2030.
1
8
1
41
1,042
$NWBO #DCVax 𝗧𝗛𝗘 𝗦𝗔𝗨𝗗𝗜 𝗗𝗖𝗩𝗔𝗫 𝗣𝗟𝗔𝗡 𝗗𝗢𝗘𝗦 𝗡𝗢𝗧 𝗡𝗘𝗘𝗗 𝗔 𝗦𝗔𝗨𝗗𝗜 𝗙𝗔𝗖𝗧𝗢𝗥𝗬 𝗧𝗢 𝗦𝗧𝗔𝗥𝗧. That changes the order of investment. Northwest could supply an authorized Saudi program from its existing British manufacturing operation while a regional partner establishes access and develops local production. The company would bring the vaccine, clinical evidence, intellectual property and manufacturing expertise. The partner would bring regional execution and whatever financial commitments the definitive agreement secures. That is the commercial inflection point to watch: whether assets Northwest has already developed can support international expansion without Northwest having to build and finance every part of it itself. 𝗦𝗣𝗜𝗠𝗔𝗖𝗢 𝗜𝗦 𝗔𝗟𝗥𝗘𝗔𝗗𝗬 𝗙𝗜𝗟𝗜𝗡𝗚. On November 16, Genetix announced that Saudi marketing applications for LYFGENIA and ZYNTEGLO are under SFDA review through SPIMACO. Both are FDA-approved therapies made from patients’ own blood stem cells. Genetix announced its SPIMACO agreement on June 23. Confirmation of Saudi review followed 146 days later. The submission dates are undisclosed, so that measures the interval between announcements rather than regulatory review time. It nevertheless demonstrates execution. SPIMACO is responsible for authorization and commercialization, with Saudi manufacturing planned. The same company signed Northwest’s August DCVax-L memorandum. Its operating scale also matters: SAR 1.70 billion in reported 2025 revenue and SAR 184.4 million in net profit, up more than sevenfold. Its SPIMACO Bio subsidiary targets biological, gene and cell therapies. Northwest’s prospective partner is already doing the regulatory and commercial work contemplated for other individualized cell products. 𝗧𝗪𝗢 𝗔𝗚𝗥𝗘𝗘𝗠𝗘𝗡𝗧𝗦 𝗔𝗗𝗗𝗥𝗘𝗦𝗦 𝗧𝗪𝗢 𝗣𝗔𝗥𝗧𝗦 𝗢𝗙 𝗧𝗛𝗘 𝗣𝗥𝗢𝗕𝗟𝗘𝗠. Northwest’s August 6 MOU proposes a commercial relationship. It is non-binding, with the following division of responsibilities contemplated: • SPIMACO handles the Saudi application, marketing, sales and distribution. • Northwest provides the scientific evidence, support and manufactured vaccine. • Northwest retains its intellectual property. • Revenue sharing is contemplated, with separate agreements for Saudi manufacturing and technology transfer. Glioblastoma comes first. Other indications and Gulf territories can follow by mutual agreement. Then came the regulator-to-regulator agreement. On November 16, MHRA announced a memorandum with SFDA, signed by Lawrence Tallon and Hisham Aljadhey at the DIA–MHRA summit in London, with Anthony Harnden present. Its scope expressly includes biologics and advanced therapies. Rare diseases are among its initial priorities. The company agreement would organize production, payment and distribution. The regulatory agreement establishes a framework for cooperation, information exchange and shared expertise. A British-manufactured, patient-specific therapy seeking Saudi access sits directly within the kinds of cross-border problems those arrangements are intended to address. 𝗦𝗣𝗜𝗠𝗔𝗖𝗢 𝗣𝗔𝗬𝗦 𝗙𝗢𝗥 𝗠𝗔𝗡𝗨𝗙𝗔𝗖𝗧𝗨𝗥𝗜𝗡𝗚 𝗞𝗡𝗢𝗪𝗟𝗘𝗗𝗚𝗘. Its other transactions show the commercial model. Genetix receives technology-transfer payments and a double-digit royalty. Shilpa Biologicals’ agreement includes upfront payments, development and commercial milestones, and product-supply revenue, followed by phased localization. Those terms belong to those companies. They show what can be negotiated. For Northwest, the potential value extends beyond supplying individual doses. The ability to reproduce the manufacturing process in another country is itself an asset. Saudi Arabia has a strong incentive to acquire that capability. King Faisal Specialist Hospital reported that local CAR-T production reduced treatment cost from roughly SAR 1.3 million to SAR 250,000 and manufacturing time from 28 days to 12–14. Those are CAR-T figures. They explain the economic motivation behind the Kingdom’s investment in advanced manufacturing. Its National Biotechnology Strategy targets regional leadership by 2030 and global leadership by 2040. Northwest’s proposed sequence fits that ambition: supply first, then negotiate the transfer of production capability while retaining IP. 𝗦𝗔𝗪𝗦𝗧𝗢𝗡 𝗣𝗥𝗢𝗩𝗜𝗗𝗘𝗦 𝗧𝗛𝗘 𝗜𝗡𝗜𝗧𝗜𝗔𝗟 𝗕𝗔𝗦𝗘. Sawston received its MHRA commercial manufacturing licence in March 2023. Northwest’s announcement described permissions to export cellular products and import cellular starting materials into Britain. Northwest acquired Advent, Sawston’s operator, in October 2025. The manufacturing business is now inside Northwest; the building is leased. An initial Saudi program could connect local collection and treatment to British production, subject to the required product, site, tissue-shipment and import permissions. Northwest historically estimated capacity of approximately 450–500 patients annually in the first two suites, occupying about 4,400 square feet of an 88,345-square-foot building. That describes potential production capacity, rather than spare slots available for a Saudi program. Expansion remains a separate issue. Grade C construction began in November 2025, followed by a disclosed pause while engineering continued. The second-quarter filing discussed additional tumor-lysate processing capacity before completion. The latest filing does not establish that the new suite is finished. On October 26, Northwest announced expansion of its technical team supporting manufacturing scale-up and other priority operations, including restarting U.S. manufacturing. The distinction is useful: an operating production base can support an initial plan while additional capacity is developed. 𝗥𝗘𝗚𝗨𝗟𝗔𝗧𝗢𝗥𝗬 𝗞𝗡𝗢𝗪𝗟𝗘𝗗𝗚𝗘 𝗖𝗔𝗡 𝗧𝗥𝗔𝗩𝗘𝗟 𝗕𝗘𝗙𝗢𝗥𝗘 𝗣𝗥𝗢𝗗𝗨𝗖𝗧𝗜𝗢𝗡 𝗠𝗢𝗩𝗘𝗦. SFDA issued its NADR rare-disease framework on August 5. Northwest announced its MOU on August 6. The framework took effect September 5. NADR covers qualifying pharmaceutical and biological products, including products still in development. Prior foreign approval is not universally required. Its designation-assessment target is 20 working days from a complete submission, subject to information requests. A marketing application should follow within six months of designation. The framework includes rolling submission, conditional approval and natural-history comparators where concurrent controls are infeasible. For manufacturing sites in listed countries, including Britain, it provides inspection flexibility supported by GMP certificates, the site master file and inspection documentation. Sawston already has a British regulatory record. Relevant existing documentation could support Saudi assessment without first relocating production. NADR also permits established platform knowledge and related manufacturing data to support subsequent submissions. That makes accumulated manufacturing knowledge potentially useful across both territories and future development programs. Each proposed indication still needs an adequate evidence case, but every part of the supporting work need not necessarily begin again. Regulatory information exchange also remains separate from commercial technology transfer. Cooperation between agencies does not automatically license Northwest’s manufacturing process to another company. 𝗧𝗛𝗘 𝗘𝗩𝗜𝗗𝗘𝗡𝗖𝗘 𝗣𝗔𝗖𝗞𝗔𝗚𝗘 𝗔𝗟𝗥𝗘𝗔𝗗𝗬 𝗛𝗔𝗦 𝗦𝗨𝗕𝗦𝗧𝗔𝗡𝗖𝗘. DCVax-L’s published externally controlled survival analysis reported: • Newly diagnosed glioblastoma: median survival of 19.3 versus 16.5 months. • Five-year survival: 13.0% versus 5.7%. • Recurrent glioblastoma: median survival of 13.2 versus 7.8 months. Subsequent patient-level matching analyses tested the survival finding using individual records from other trials. SFDA would assess that package. The relevance of NADR is that it provides mechanisms for discussing evidence appropriate to rare diseases and difficult trial settings. Britain recognized the product’s promise much earlier: DCVax-L received the first UK Promising Innovative Medicine designation in 2014. 𝗕𝗥𝗜𝗧𝗜𝗦𝗛 𝗔𝗣𝗣𝗥𝗢𝗩𝗔𝗟 𝗖𝗛𝗔𝗡𝗚𝗘𝗦 𝗧𝗛𝗘 𝗦𝗔𝗨𝗗𝗜 𝗢𝗣𝗧𝗜𝗢𝗡𝗦. Some Saudi routes can be pursued beforehand. The Breakthrough Medicine Program requires that a product has no foreign marketing authorization when designation is requested. Serious disease, unmet need, potential clinical advantage and benefit–risk must also satisfy SFDA. The timing of that request therefore matters. For the complete-data route, the guidance describes approximately 30 working days for designation review, 30 working days to submit the application after designation and a 60-working-day scientific assessment. Information requests affect elapsed time. Crucially, the guidance permits access negotiations with healthcare entities to proceed alongside application review. Regulatory assessment and preparation for delivery can move together. Casgevy demonstrates that the program can accommodate an individualized cell therapy. Its Saudi approval on January 9, 2024 followed British approval by less than two months. Its logistics are also relevant: collection at an authorized center, specialist manufacturing and return of the product for treatment. 𝗔 𝗦𝗔𝗨𝗗𝗜 𝗙𝗜𝗟𝗜𝗡𝗚 𝗖𝗔𝗡 𝗠𝗔𝗧𝗧𝗘𝗥 𝗕𝗘𝗙𝗢𝗥𝗘 𝗔𝗣𝗣𝗥𝗢𝗩𝗔𝗟. SFDA’s special-access guideline recognizes three alternative eligibility conditions: • Matching product registration by a listed reference regulator, including MHRA. • Approval or permission from a reference regulator under the relevant access-program provision. • A matching product application already under Saudi registration. A Saudi filing can therefore satisfy an eligibility condition for a separately authorized access program. Northwest’s existing UK compassionate-use service makes the second route worth clarifying directly with SFDA. The English text refers to permission for the program; the Arabic wording refers to the drug. British approval would establish the reference-registration alternative while changing eligibility for a new Breakthrough request. The strategic task is to select and sequence the available routes as regulatory status changes. The October special-access guideline includes rare-disease requests, a seven-working-day response target and permissions lasting up to 12 months, renewable. Program and import permissions remain necessary. The applicant funds the program and commits to free product for enrolled patients under the guideline’s conditions. That makes funding part of the access plan from the outset. Someone must cover manufacture, logistics and care. 𝗢𝗡𝗘 𝗖𝗢𝗟𝗟𝗘𝗖𝗧𝗜𝗢𝗡 𝗖𝗔𝗡 𝗦𝗨𝗣𝗣𝗢𝗥𝗧 𝗬𝗘𝗔𝗥𝗦 𝗢𝗙 𝗧𝗥𝗘𝗔𝗧𝗠𝗘𝗡𝗧. DCVax-L requires suitable tumor material and immune cells. Tumor material must be preserved under the appropriate manufacturing protocol. Routine formalin-fixed pathology material cannot simply substitute. Suitable previously banked material may sometimes be available. The immune-cell starting material comes from leukapheresis. NHS Blood and Transplant’s collaboration supports collection and specialist processing. Initial work involves Leeds and Oxford, with expansion being explored across a service operating apheresis units in ten English cities. NHSBT’s announcement describes the intended scope as glioblastoma “as well as all solid tumours.” That is a broad development ambition for the platform, with evidence and authorization required for particular uses. The manufacturing model explains why collection capacity matters so much. Northwest reports approximately eight days of production plus release testing to produce a multi-year set of frozen doses. A successful collection and manufacturing cycle can support repeated treatment. Each subsequent dose does not require another complete production cycle. That separates three operational demands: collecting new patients, manufacturing their batches, and storing and administering the resulting doses. It also supports centralized production with repeated international shipments. The expense of manufacture is concentrated early. Payment timing is a contractual question; multi-year doses do not automatically mean prepaid revenue. Saudi Arabia already has relevant infrastructure. King Faisal Specialist Hospital has treated more than 200 CAR-T patients and developed local production. Casgevy has an authorized Saudi treatment-center model. Apheresis, patient identification, frozen-product handling and specialist administration are established capabilities in the Kingdom. 𝗧𝗛𝗘 𝗖𝗛𝗘𝗖𝗞𝗣𝗢𝗜𝗡𝗧 𝗖𝗢𝗡𝗡𝗘𝗖𝗧𝗜𝗢𝗡 𝗘𝗫𝗧𝗘𝗡𝗗𝗦 𝗧𝗛𝗘 𝗢𝗣𝗣𝗢𝗥𝗧𝗨𝗡𝗜𝗧𝗬. SPIMACO Bio’s Shilpa agreement covers PD-1 biosimilars. Shilpa’s disclosed development pipeline includes pembrolizumab and nivolumab, although the agreement announcement does not individually identify the licensed molecules. Pembrolizumab is paired with dendritic-cell vaccination in UCLA’s recurrent-glioblastoma trial and a Pittsburgh ovarian-cancer study listing Northwest as a collaborator. Northwest’s prospective Saudi partner is building capabilities relevant to both dendritic-cell vaccination and the checkpoint drugs used alongside it. That provides a commercial and scientific basis for exploring a broader regional cancer-immunotherapy program around the initial DCVax-L collaboration. 𝗣𝗔𝗥𝗟𝗜𝗔𝗠𝗘𝗡𝗧 𝗜𝗦 𝗣𝗥𝗘𝗦𝗦𝗜𝗡𝗚 𝗢𝗡 𝗧𝗛𝗘 𝗣𝗔𝗧𝗜𝗘𝗡𝗧’𝗦 𝗙𝗜𝗥𝗦𝗧 𝗕𝗢𝗧𝗧𝗟𝗘𝗡𝗘𝗖𝗞. Ruth Jones’s questions 41560 and 41561 seek national brain-tumor preservation standards, retention of suitable surplus tissue and consideration of preservation in the Chalmers review. Answers are requested for November 17. NHS England has completed a freezer-capacity gap analysis. Published answers have not supplied a funded rollout timetable or identified all sites receiving additional capacity. The connection to vaccine access is direct: NHSBT supports the blood-derived input; preservation policy protects the tumor-derived input. A treatment can become available after surgery. The opportunity to preserve the patient’s tissue may already have passed. On November 4, Sharon Hodgson raised Braelyn’s case and access to DCVax-L in the Commons. The government committed to urgent examination by the Health Secretary. The October 14 brain-cancer initiative promised the Chalmers review, a subsequent national action plan and a national clinical lead. This gives Parliament identifiable implementation questions to pursue: preservation standards, funded infrastructure and responsibility for getting patients through the process. 𝗟𝗔𝗪𝗥𝗘𝗡𝗖𝗘 𝗧𝗔𝗟𝗟𝗢𝗡 𝗖𝗢𝗡𝗡𝗘𝗖𝗧𝗦 𝗥𝗘𝗚𝗨𝗟𝗔𝗧𝗜𝗢𝗡 𝗪𝗜𝗧𝗛 𝗗𝗘𝗟𝗜𝗩𝗘𝗥𝗬. Tallon is MHRA’s chief executive and chairs its highest executive decision-making body. Previously, he was deputy chief executive at Guy’s and St Thomas’ NHS Foundation Trust, overseeing strategy, technology and innovation. His experience includes running healthcare services as well as leading their regulator. His Saudi relationship predates this summit. SFDA documented a bilateral meeting between Tallon and Aljadhey in October 2025 concerning regulatory cooperation and medicine quality, safety and efficacy. The new memorandum develops an established relationship. Tallon has now signed the Saudi agreement and is co-chairing the summit session where Dr. Annalisa Jenkins will deliver a keynote and join the panel. Northwest appointed Jenkins in April to support its dendritic-cell platform, regulatory strategy and commercialization, explicitly including broader solid tumors and rare cancers. Her responsibilities overlap closely with the summit’s discussion of investment, policy and international delivery. The programme lists her under The Conscience Collective and Genomics England. This is a substantive institutional connection. It does not establish a private DCVax decision. 𝗧𝗛𝗘 𝗗𝗔𝗧𝗘𝗦 𝗧𝗢 𝗪𝗔𝗧𝗖𝗛. November 17 begins with the summit’s advanced-therapy and rare-disease session, involving MHRA, NICE, patient advocates and investors. The international-regulation session includes Aljadhey and MHRA’s James Pound. The closing plenary begins at 15:15 London time, 10:15 a.m. Eastern, with Tallon co-chairing and Jenkins speaking. The programme also includes an MHRA parliamentary reception and closing commitments involving the science minister. The summit is already being used for announcements: the Saudi MOU and MHRA’s Women’s Health Programme. Tallon’s opening recap emphasized faster trials, recruitment and translating science into patient benefit. Also on November 17 are the requested tissue-preservation answers and a Westminster Hall debate on MHRA performance. Its advertised scope concerns safety, transparency and accountability. On November 18, Siobhain McDonagh has a PMQs slot. Her supplementary topic has not been published. The Chalmers review was asked to report within three months of the October 14 announcement. That points to mid-January 2027, approximately January 14 by calendar arithmetic. A separate exact publication date has not been announced. The national action plan follows. These are opportunities for specific commitments, rather than dates assigned to a DCVax approval. 𝗧𝗛𝗘 𝗖𝗢𝗠𝗠𝗘𝗥𝗖𝗜𝗔𝗟 𝗧𝗘𝗦𝗧 𝗜𝗦 𝗪𝗛𝗢 𝗔𝗦𝗦𝗨𝗠𝗘𝗦 𝗧𝗛𝗘 𝗢𝗕𝗟𝗜𝗚𝗔𝗧𝗜𝗢𝗡𝗦. Northwest’s November 13 filing still describes negotiations toward a definitive Saudi agreement and continued engagement in the British review. A Saudi DCVax filing has not been publicly verified. The next agreement becomes consequential through its terms. Development funding, technology-transfer payments, purchase commitments or funded access arrangements could change how much expansion Northwest must finance from its own balance sheet. Those commitments have not been disclosed for Northwest. They are what investors should examine when a definitive agreement appears. The financial stakes are substantial. Northwest reported $725,000 in cash at September 30 and significant current liabilities, while also disclosing a subsequent October financing agreement. SPIMACO’s resources become useful to Northwest through enforceable obligations: who pays, when payment occurs, who performs the work and what happens if milestones are missed. An agreement assigning those responsibilities could strengthen Northwest in three ways: • Share the cost of expansion. • Put regional execution in the hands of an experienced partner. • Create income opportunities from existing production, technology and expertise. That is a more consequential development than another statement of intent. 𝗧𝗛𝗘 𝗡𝗘𝗫𝗧 𝗦𝗧𝗘𝗣𝗦 𝗖𝗔𝗡 𝗕𝗘 𝗠𝗘𝗔𝗦𝗨𝗥𝗘𝗗. The milestones are a definitive agreement, an appropriate SFDA designation or filing, an authorized access route, named treatment centers and the manufacturing and import arrangements required to deliver doses. The work can overlap. Regulatory review, access negotiations and preparation of treatment centers can proceed alongside one another where the applicable rules permit. The regional opportunity also extends beyond Saudi Arabia. Northwest’s MOU allows additional Gulf territories by agreement. SFDA became the first full ICMRA member from the Middle East and North Africa in 2025, and its cooperation with Bahrain includes a 2024 regulatory agreement. Each jurisdiction retains its own requirements, but Northwest would not be developing regional relationships from nothing. 𝗙𝗥𝗢𝗠 𝗔𝗡𝗡𝗢𝗨𝗡𝗖𝗘𝗠𝗘𝗡𝗧𝗦 𝗧𝗢 𝗔𝗖𝗖𝗘𝗦𝗦. NHSBT helps organize the route into manufacturing. Northwest brings the technology and production. SPIMACO offers a prospective route into another healthcare system. The MHRA–SFDA agreement gives the regulators a framework for working together. Each addresses a different part of the same problem: making a personalized treatment deliverable across borders. The opportunity is to use existing production, retain the value of the intellectual property and develop local manufacturing in stages, with a partner carrying defined responsibilities. For patients, preparation cannot wait for every institutional decision. A regulator can authorize treatment later. A company can expand a factory later. Neither can recover a patient’s discarded tumor. The route begins with suitable tissue and ends with a released dose in a treating physician’s hands. The decisive next announcement would identify who funds that route, who supplies the vaccine and where patients can receive it. That is the agreement that would turn Northwest’s Saudi opportunity into an operating business.
1
10
1
41
1,141
🚨 Closing soon: i4i PDA NICE early use recommendation - October 2026 Our Invention for Innovation (i4i) Product Development Awards (PDA), aims to generate real world evidence for products that have been recommended for early use in the NHS through @NICEComms early use assessment. ⏰ Applications close 2 December at 1pm Apply now ➡️ nihr.ac.uk/funding/i4i-produ… #ResearchFunding #HealthInnovation #i4i #NICE
1
15
804
#dcvax $nwbo #gbm I cannot believe that $nwbo will not be in attendance at the DIA/MHRA Global summit: diaglobal.org/Conference-Lis…
4
1
21
2,007
#dcvax $nwbo #gbm DIA/MHRA: AI-driven drug discovery Advanced therapies & cell & gene therapy Real-world evidence & digital diagnostics Clinical trials, preventative medicines & rare diseases investorshub.advfn.com/board… linkedin.com/posts/dia_we-ar…
1
13
763
A novel dendritic cell therapy shows early promise for breast cancer leptomeningeal disease. At #SNO26, Moffitt’s Peter Forsyth, MD (@PeterForsyth27), discusses research findings showing immune activation, manageable toxicity and a median overall survival of 16.2 months. #MoffittSNO26
2
17
2
43
2,729
Peter Davis retweeted
$NWBO 17-acre property has been retained as a potential shipping hub since 2018. This year this property might serve the company in a different way! January 2026 SPIMACO announces the launch of SPIMACO Bio spimaco.com.sa/spimaco-annou… March 10, 2026 BioNTech founders plan exit to set up new venture, shares slump reuters.com/business/healthc… 10Q from May 2026 sec.gov/ix?doc=/Archives/edg… If zoned for residential development, the Company has been advised that its property would be extremely valuable. 10Q from August 2026 sec.gov/ix?doc=/Archives/edg…
2
4
39
1,267
Peter Davis retweeted
Linda Liau delivered more solid numbers yesterday at SNO in Philly. Oral presentation from the randomized trial. DC vaccine first, then Keytruda. Median survival more than doubled. 555 days vs 271. Same drugs. Different order. Clear win. Sequencing matters for the immune system. The DC platform keeps delivering real results. #DCVaxWorks $NWBO
2
39
3
160
11,842
Peter Davis retweeted
CAR-T engineers T cells to carry a synthetic receptor aimed at a single tumor antigen, such as CD19. That precision is a strength, but it's also a weakness: tumors can escape by losing that one target. What about letting DCs which have hundreds of tumor-associated peptides on their cell surface to prime t-cells ex vivo? Should T-cells primed this way be better to get rid of cancer cells than those from CAR-T? Investors at Norway's sovereign wealth fund should appreciate this distinction.
#dcvax $nwbo #gbm Pawel Kalinski Poster: 18th International Symposium on Dendritic Cells 2026: Polarized Dendritic Cells Are Efficient Ex Vivo Inducers of Multi-Epitope-Specific T Cells for Adoptive Cancer Therapy (#274) dc-cells-2026.p.asnevents.co… investorshub.advfn.com/board…
2
10
166
#dcvax $nwbo #gbm Pawel Kalinski Poster: 18th International Symposium on Dendritic Cells 2026: Polarized Dendritic Cells Are Efficient Ex Vivo Inducers of Multi-Epitope-Specific T Cells for Adoptive Cancer Therapy (#274) dc-cells-2026.p.asnevents.co… investorshub.advfn.com/board…
3
1
25
1,323
I would be so grateful for a follow & RT My daughter wasn't a celebrity. She was just an ordinary young woman whose life was cruelly cut short by brain cancer. I'm trying to raise awareness of glioblastoma, a grade 4 brain tumour that took Charlotte when she was just 19 years old on 24th February 2016 I've been sharing her journey, hoping to help others understand the reality of living with this devastating disease. Thank you to everyone who follows, shares and helps keep her memory alive. charlottesbag.org/ She shared her journey openly on her YouTube channel. Her final video was filmed on 4 February 2016, the day before she went into a coma. youtube.com/watch?v=bh5sswba…
40
323
18
671
10,701
#dcvax $nwbo #gbm Latest Linda Liau co-authored paper: Clinically-relevant pathological discordance in multicentric IDH-mutant gliomas: a single institution case series 11 November 2026 link.springer.com/article/10… investorshub.advfn.com/board…
12
1
54
1,586
#dcvax $nwbo #gbm Something to keep an eye on.. £20m UK programme launched to strengthen regulatory science and healthcare innovation September 22, 2026 investorshub.advfn.com/board…
1
20
761
Peter Davis retweeted
$NWBO Cancer Vaccines can be applied to blood cancers! Keep in mind the DCs trained by NWBO's DCVax technologies are quite different from the ones mRNA cancer vaccines are dealing with. That's why DC vaccine can trigger intense anti-tumor immune response and make tumors disappear within weeks.
$NWBO DC vaccine for blood cancers! Personalized vaccine for patients with AML Contact PI/Project LeaderAVIGAN, DAVID E. reporter.nih.gov/search/NhWt… We are completing a phase II study in which patients with AML who achieve remission following standard therapy undergo serial vaccination with DC/AML fusions. Vaccination resulted in the dramatic expansion of AML specific lymphocytes in the peripheral blood and bone marrow. Remarkably, despite a median age of 60 with predominant intermediate and high risk disease, 75% of patients remain in remission at a median of 4 years of follow up.
1
19
1
76
2,518
Peter Davis retweeted
$NWBO It makes sense now that Pfizer sponsored the conference on therapeutic cancer vaccine in January. Dr. David Avigan was among the coauthors of the JAMA paper and he was also involved in the p3 trial. prnewswire.com/news-releases… nitter.gq/d_stock07734/status/21… nitter.gq/d_stock07734/status/21… newswise.com/articles/the-ca…
$NWBO A Harvard-affiliated hospital? Beth Israel Deaconess Medical Center, perhaps. Dr. David Avigan has run a long series of DC vaccine trials there, across a range of targets. As for the other institutions, I suspect it’s fairly obvious which ones. How many institutions have actually run early phase DC vaccine trials on advanced targets and produced amazing results? Very few! For clinical development of the technologies it has in-licensed from multiple institutions, including Roswell Park, Pittsburgh, a Harvard-affiliated hospital, and others, the Company initially focused on academic trials by investigators at those institutions. A Phase 1 Study of Vaccination With Dendritic Cell (DC)/​Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma clinicaltrials.gov/study/NCT… Dendritic Cell/​AML Fusion Cell Vaccine Following Allogeneic Transplantation in AML Patients clinicaltrials.gov/study/NCT… DC/​AML Fusion Cell Vaccine vs Observation in Patients Who Achieve a Chemotherapy-induced Remission clinicaltrials.gov/study/NCT… Vaccination With Dendritic Cell/​Tumor Fusions With Autologous Stem Cell Transplants in Patients With Multiple Myeloma clinicaltrials.gov/study/NCT… The Use of Dendritic Cell/​Tumor Fusions as a Novel Tumor Vaccine in Patients With Multiple Myeloma clinicaltrials.gov/study/NCT… Blockade of PD-1 in Conjunction With the Dendritic Cell/​Myeloma Vaccines Following Stem Cell Transplantation clinicaltrials.gov/study/NCT… Blockade of PD-1 in Conjunction With the Dendritic Cell/​AML Vaccine Following Chemotherapy Induced Remission clinicaltrials.gov/study/NCT… Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF clinicaltrials.gov/study/NCT… The Use of Dendritic Cell/​Tumor Hybridomas as a Novel Tumor Vaccine in Patients With Advance Melanoma clinicaltrials.gov/study/NCT… A Phase I/​II Study to Assess the Safety and Efficacy of Vaccinations With Allogeneic Dendritic Cells: Autologous Tumor-Derived Cells Subjected to Electrofusions in Patients With AJCC Stage IV Renal Cell Carcinoma clinicaltrials.gov/study/NCT… Vaccination of Patients With Breast Cancer With Dendritic Cell/​Tumor Fusions and IL-12 clinicaltrials.gov/study/NCT… Vaccination of Patients With Ovarian Cancer With Dendritic Cell/​Tumor Fusions With Granulocyte Macrophage Colony-stimulating Factor (GM-CSF) and Imiquimod clinicaltrials.gov/study/NCT… PD-1 Alone or With Dendritic Cell/​Renal Cell Carcinoma Fusion Cell Vaccine clinicaltrials.gov/study/NCT… Dendritic Cell (DC)/​Myeloma Fusions in Combination With Nivolumab in Patients With Relapsed Multiple Myeloma clinicaltrials.gov/study/NCT…
1
10
1
47
1,636
Peter Davis retweeted
$NWBO From 10Q New Clinical Trials With In-Licensed Technologies; Buildout of Team. For clinical development of the technologies it has in-licensed from multiple institutions, including Roswell Park, Pittsburgh, a Harvard-affiliated hospital, and others, the Company initially focused on academic trials by investigators at those institutions. Those academic programs are continuing, and the Company is also involved as previously reported, but a series of institutional changes, moves of key personnel and government funding changes have impacted them. So, in parallel the Company has built a dedicated operating team with the necessary range of technical expertise to develop and carry out Company-developed and Company-sponsored clinical trials with these in-licensed technologies. The team has been trained, has developed the necessary standard operating procedures (SOPs) and regulatory documents, has evaluated a variety of types and stages of cancers for the initial indications, has discussed these potential indications with clinicians at multiple institutions, and has determined the indication and focus for the initial Company clinical trial. sec.gov/ix?doc=/Archives/edg… So all those proof-of-concept DC vaccine trials from multiple institutions that produced amazing results could be connected to $NWBO. Recall those DC vaccine trials in which DC vaccines were combined with either anti-viral vaccines (flu vaccine) or anti-bacterial vaccines such as tetnaus vaccine or pneumococcal vaccine or both to treat tough targets and delivered amazing results. $NWBO may own those technologies. Here comes the interesting part. The massive vaccine manufacturing facility of 450k sq ft that Saudi Arabia is about to complete ASAP can produce some of anti-viral/anti-bacterial vaccines. The Saudis did see the important potential of DCVax technologies and they move fast to embrace it! vaccine.com.sa/
2
10
1
53
2,071
Peter Davis retweeted
$NWBO It would be a fantastic partnership. Worth noting that the Norwegian Wealth Fund owns 1.67% of Terumo about $339 million. Terumo BCT makes the leukapheresis system, the workhorse for collecting the mononuclear cells that cell therapies are built from. The Fund also holds Thermo Fisher, Samsung Biologics, WuXi Biologics, Charles River, Illumina, Lonza, Sartorius and Repligen, effectively the entire manufacturing stack for cell therapy. It even holds a stake in Imugene, a small Australian company developing off-the-shelf allogeneic CAR-T. imugene.com/ So another non-binding MOU?! nitter.gq/d_stock07734/status/21…
Replying to @d_stock07734
That would be a great partnership. Norwegian Wealth fund has deeeeeeeeep pockets, and has been selling off american treasuary bond and stocks from many american cooperations since this summer.
2
4
38
1,263
$NWBO @NorthwestBio Simple Financials after latest 10-Q. NWBO needs to get decision by EOY, this continued conversion of debit to shares can't continue in 2027 IMO at our current Share Price with the pace that occurred in 2026. We need the Major Catalyst decision (MHRA) and then Cash infusion with partners, collaborators etc., of course Revenue on a MHRA approval will go along way but revenue will take some time to get the Cash streams generated and into the 10-Q's, plus we will be waiting on NICE cost-efficiency decision for insurance payments for DCVAX-L. The Wild card is the pending Litigation and Judge's Algo decision and what may or may not happen with settlements. We had one settlement which was put in a Trust until other potential settlements materialize.
9
14
98
3,242